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Abstract
A total of 92 isolates of Mycobacteriurn tuberculosis consisting of equal numbers of
sensitive and resistant strains was tested for their susceptibility to sulbactam and
ampicillin (in the ratio of 1:2) on Lowenstein-Jensen (LJ) and 7H11 agar media. The
geometric mean MIC was 63.97 µg/ml for the drug sensitive strains and 65.92 µg/ml
for the resistant strains, and the overall mean was 65.01 µg/ml. The high MIC on LJ
medium could be attributed to the higher protein content which resulted in greater
binding of sulbactam/ampicillin. On the other hand, the geometric mean MIC on
7H11 medium was 26.73 µg/ml for sensitive strains and 23.82 µg/ml for resistant
strains; the overall mean being 25.23 µg/ml. Although these MlCs of sulbactam-
ampicillin are higher than those reported earlier, they can be easily achieved in
serum. Further studies on experimental tuberculosis and in humans will be needed
to prove the efficacy of sulbactam/ampicillin in the treatment of patients with
multidrug resistant tuberculosis.
Introduction
Multidrug-resistant tuberculosis (MDR-TB) is rapidly emerging as a
major problem in the treatment of tuberculosis both in the developed
countries and in the developing countries (Riley, 1993; Nagpaul,
1994). The prognosis for chemotherapy in tuberculosis patients with
Mycobacterium tuberculosis resistant to rifampicin and isoniazid is poor
(Hong Kong Chest Services/British Medical Research Council, 1992;
Goble et al., 1993; Rema Mathew et al., 1993). In these patients
administration of effective treatment with regimens containing at least
two or three drugs to which the organisms are sensitive is essential for
curing the disease and blocking the transmission (Goble et al., 1993).
A large number of new drugs has been introduced in recent years for
the treatment of bacterial, parasitic, fungal and viral diseases. In
contrast, very few major new antituberculosis agents have become
available since rifampicin was introduced in the early 1970s (O’Brien
and Snider, 1985). The current TB epidemic associated with HIV
infection and the occurrence of MDR-TB have led to the need for
rapid development of new antituberculosis drugs and it has become
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necessary to screen new drugs for antituberculosis activity (Mitchison
et al., 1988; Parenti, 1989). Hence, systematic evaluation of new anti-
tuberculosis drugs is being undertaken at this Centre (Selvakumar et
al., 1992; Venkataraman et al., 1992a,b,c; Herbert et al., 1997; Kamala
et al., 1997).
Even though the ß-lactam drugs are ineffective against myco-
bacteria which are ß-lactamase producing organisms, combinations of
ß-lactam antibiotics with ß-lactamase inhibitors have been shown to
have activity against these organisms (Casal et al., 1987; Sorg and
Cynamon, 1987; Parenti, 1989; Nadler et al, 1991). Among these,
sulbactam/ampicillin (SA) has been shown to have a minimal inhibi-
tory concentration (MIC) of 8 µg/ml against M. tuberculosis isolates
(Sorg and Cynamon, 1987).
The present study was carried out to determine the MICs of SA
for drug sensitive and drug resistant M. tuberculosis isolates from
southern Indian patients both on Lowenstein-Jensen (LJ) and
Middlebrooks 7H11 media to see whether the high protein content
of LJ medium would have any effect on the MICs.
Materials and methods
Bacterial strains
A total number of 46 Mycobacterium tuberculosis isolates from
tuberculosis patients admitted to various clinical trials at the
Tuberculosis Research Centre (TRC), Madras, which were sensitive to
streptomycin (S), isoniazid (H) and rifampicin (R) and 46 isolates
which were SHR/HR resistant were used in the study.
Drug containing medium
Pure powders of sulbactam and ampicillin (kindly provided by
Unichem Laboratories Ltd, India) were dissolved in sterile distilled
water and added to LJ medium before inspissation of the slopes and
sterile 7H11 medium containing oleic acid-albumin-dextrose com-
plex (OADC) enrichment before pouring the plates to get final con-
centrations of 1, 2, 4, 8, 16, 32, 64 and 128 µg/ml ampicillin with a
sulbactam:ampicillin ratio of 1:2.
Sensitivity testing
From 2- to 3-week-old cultures of each M. tuberculosis strain on LJ,
standard bacterial suspensions of 4 mg/ml were prepared in bijoux
bottles with sterile distilled water and beads and shaken for uniform
distribution. One loopful each of the suspension was inoculated onto
two drug-free LJ slopes and one drug containing-LJ slope of each con-
centration with a 3 mm diameter loop, and 10 µl each was inoculated
onto duplicate sectors of drug-free and drug-containing 7H11 plates
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with a micropipette. The inoculated media, of 7H11 plates in poly-
thene bags, were incubated at 37°C and read at the end of 4 weeks.
The lowest concentration of the drug which inhibited growth to less
than twenty colonies compared with at least numerous discrete
colonies (++ growth) on drug-free medium was taken as the minimal
inhibitory concentration (MIC).
Results
The frequency distribution of MICs of SA on LJ medium is presented
in Table 1. The MICs ranged from 8 to >128 µg/ml. For the majority
of the strains, SA had high MICs on LJ medium. Of the 92 strains
tested on LJ medium, the MIC was >64 µg/ml for 66 (71.7%) and the
overall geometric mean MIC (GM) was 65.01 µg/ml. The GM was
63.97 µg/ml for the 46 drug sensitive strains and 65.92 µg/ml for
the 46 drug resistant strains. The difference in GM between the drug
sensitive and the drug resistant strains was not significant (p >0.5).
The frequency distribution of MICs of SA on 7H11 medium is
shown in Table 2. The MICs of SA were lower on 7H11 compared
with that on LJ media and ranged from 8 to 64 µg/ml. The overall GM
for the 64 strains tested on 7H11 was 25.23 µg/ml which was
significantly lower than that on LJ medium (p <0.001). For none of
the strains tested, the MIC was >64 µg/ml and for 47 of the 64 strains
(73.4%) the MIC was < 32 µg/ml. The GM was 26.73 µg/ml for the
31 drug sensitive strains and 23.82 µg/ml for the 33 drug resistant
strains. Again, this difference in GM of drug sensitive and drug
resistant strains was not significant (p >0.5).
Table 1 Frequency distribution for MIC of sulbactam/ampicillin in
µg/ml of ampicillin against SHR sensitive and SHR/HR resistant isolates
of M. tuberculosis on LJ medium
M. tuberculosis MIC (µg/ml of ampicillin) of SA on LJ:
isolates 8 16 32 64 128 >128 Total GM
SHR sensitive 2 1 8 20 14 1 46 63.97
SHR/HR sensitive 0 2 13 14 15 2 46 65.92
Total 2 3 21 34 29 3 92 65.01
137 In vitro activity of sulbactam/ampicil l in against M. tuberculosis
Table 2 Frequency distribution for MIC of sulbactam/ampicillin in
µg/ml of ampicillin against SHR sensitive and SHR/HR resistant isolates
of M. tuberculosis on 7H11 medium
M. tuberculosis MIC (µg/ml of ampicillin) of SA on 7H11:
isolates 8 16 32 64 128 Total GM
HR sensitive 5 8 8 10 0 31 26.73
SHR/HR resistant 6 9 11 7 0 33 23.82
Total 11 17 19 17 0 64 25.23
Discussion
Abraham et al. (1941) observed that M. tuberculosis was not inhibited
in vitro by high concentrations of penicillin. The penicillinase activity
of M. tuberculosis was subsequently identified (Hand and Bains, 1949;
Soltys, 1952). Later, this penicillinase was shown to be a ß-lactamase
in studies on the effect of ß-lactamase susceptible and resistant
antibiotics on the in vitro growth of M. tuberculosis (Kasik, 1964). It
was also shown that a combination of ß-lactamase stable oxacillin with
penicillin was more effective than either drug alone in inhibiting
mycobacterial growth and that this penicillin-sparing effect was due to
ß-lactamase inhibition (Kasik et al, 1967). This activity of penicillin+
lactamase inhibitor combination on M. tuberculosis was also
demonstrated in a murine model of tuberculosis (Kasik et al., 1966).
Clavulanic acid and sulbactam are specific inhibitors of ß-lactamase
which are currently used clinically to protect ß-lactamase susceptible
antibiotics (Bush, 1988). Of these two, clavulanic acid is a natural
product while sulbactam was developed later (Brown et al., 1976;
English et al., 1978). Augmentin is an oral preparation of clavulanic
acid in combination with amoxicillin. Timentin is a parental prepa-
ration of clavulanic acid with ticarcillin while Sulbacin is a parental
preparation of sulbactam with ampicillin. Ticarcillin in combination
with clavulanic acid has been studied in vitro against various
mycobacteria (Casal et al., 1989). All the M. tuberculosis, M. bovis
and M. africanurn strains were susceptible at 32 µg/rnl or less of
ticarcillin in combination with 5 µg/ml of clavulanic acid. The MIC of
amoxycillin/clavulanic acid against M. tuberculosis has been reported
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to be 4.4 µg/ml and that of sulbactam/ampicillin to be 8.8 µg/ml
(Sorg and Cynamon, 1987) In mouse foot-pad, while amoxycillin
clavulanic acid combination had no effect on the growth of M. leprae,
the same concentration of SA was found to suppress their
multiplication (Prabhakaran et al., 1992).
In the present study, the mean MICs of SA against the M. tuberculosis
were significantly lower when tested on 7H11 medium compared with
LJ medium. This was probably due to the higher protein content and
in turn higher binding of sulbactam and ampicillin in LJ medium.
Protein binding in serum has been reported to be 28% for ampicillin
and 38% for sulbactam (Wise, 1986). In connection with the results
on 7H11 medium, the overall mean MIC of SA for all the
M. tuberculosis strains tested was 25.23 µg/ml, with no significant
difference between the GM of SHR/HR resistant and SHR sensitive
strains indicating that cross resistance does not exist between SA and
SHR.
The MICs of SA in the present work were higher than the MIC
of 8 µg/ml reported earlier by Sorg and Cynamon (1987). However,
even these higher levels can be easily achieved in serum because
peak serum concentrations of >90 µg/ml of ampicillin have been
reported after intravenous dosage regimen of 2 g of ampicillin and 1 g of
sulbactam (Foulds et al., 1983), and from 5l-82 µg/ml and > 15 µg/ml
of ampicillin, respectively, after intravenous and intramuscular
administration of 1 g of ampicillin and 0.5 g of sulbactam (Foulds,
1986; Ripa et al., 1990). The other favourable features of SA are that
useful concentrations of SA can be achieved in pus, sputum and
middle ear fluid. Moreover, penetration of SA into CSF is increased
in patients with bacterial meningitis (Rodriguez et al., 1986; Foulds,
1986) and this combination has been remarkably free of major side
effects (Lees et al., 1986).
Our investigation shows that SA could be useful in the treatment of
tuberculosis, particularly in drug resistant patients. It has already been
shown that the multiplication of M. leprae in foot pads of experi-
mentally infected mice is suppressed by intramuscular administration
of SA and that SA also inhibits the growth of drug resistant M. leprae
which could grow in the presence of rifampicin or dapsone
(Prabhakaran et al., 1992). It has been shown that on log-phase
cultures of M. tuberculosis in 7H9 liquid medium SA has bactericidal
action similar to that of rifampicin and isoniazid (Herbert et al., 1997).
Further studies are required on the activity of SA on M. tuberculosis in
mouse models and in tuberculosis patients.
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